Your browser doesn't support javascript.
loading
Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.
Li, Yapeng; Zheng, Xueying; Tu, Dongsheng; Ingle, James N; Goss, Paul E; Parulekar, Wendy R; Qin, Guoyou.
Afiliação
  • Li Y; Department of Biostatistics, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Zheng X; Department of Biostatistics, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Tu D; Canadian Cancer Trials Group, Queen's University, Kingston, ON, K7L 3N6, Canada. dtu@ctg.queensu.ca.
  • Ingle JN; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Goss PE; Massachusetts General Hospital Cancer Center, Avon International Breast Cancer Research Program, Harvard Medical School, Boston, MA, USA.
  • Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, K7L 3N6, Canada.
  • Qin G; Department of Biostatistics, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China. gyqin@fudan.edu.cn.
Breast Cancer Res Treat ; 191(3): 523-533, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34825307
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article